» Articles » PMID: 31408293

Childhood Atopic Dermatitis: Current Developments, Treatment Approaches, and Future Expectations

Overview
Journal Turk J Med Sci
Specialty General Medicine
Date 2019 Aug 14
PMID 31408293
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder of childhood. Underlying factors that contribute to AD are impaired epithelial barrier, alterations in the lipid composition of the skin, immunological imbalance including increased Th2/Th1 ratio, proinflammatory cytokines, decreased T regulatory cells, genetic mutations, and epigenetic alterations. Atopic dermatitis is a multifactorial disease with a particularly complicated pathophysiology. Discoveries to date may be considered the tip of the iceberg, and the increasing number of studies in this field indicate that there are many points to be elucidated in AD pathophysiology. In this review, we aimed to illustrate the current understanding of the underlying pathogenic mechanisms in AD, to evaluate available treatment options with a focus on recently discovered therapeutic agents, and to determine the personal, familial, and economic burdens of the disease, which are frequently neglected issues in AD. Currently available therapies only provide transient solutions and cannot fully cure the disease. However, advances in the understanding of the pathogenic mechanisms of the disease have led to the production of new treatment options, while ongoing drug trials also have had promising results.

Citing Articles

Anti-Inflammatory Effects of the LK5 Herbal Complex on LPS- and IL-4/IL-13-Stimulated HaCaT Cells and a DNCB-Induced Animal Model of Atopic Dermatitis in BALB/c Mice.

Kim H, Kim S, Bae H, Choi Y, An J, Cho Y Pharmaceutics. 2024; 16(1).

PMID: 38258052 PMC: 10821371. DOI: 10.3390/pharmaceutics16010040.


A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children.

Mohamed A, El Borolossy R, Salah E, Hussein M, Muharram N, Elsalawy N Front Pharmacol. 2023; 14:1202325.

PMID: 37799965 PMC: 10547881. DOI: 10.3389/fphar.2023.1202325.


Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study.

Sowlati M, Morariu S, Orzan O, Veraldi S, Dodiuk-Gad R, Orasan R Dermatol Ther (Heidelb). 2023; 13(11):2669-2679.

PMID: 37740857 PMC: 10613178. DOI: 10.1007/s13555-023-01035-6.


Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis.

Kakkar V, Saini K, Singh K Pharmacol Rep. 2023; 75(5):1066-1095.

PMID: 37668937 PMC: 10539427. DOI: 10.1007/s43440-023-00510-3.


Pearls and Pitfalls of Weaning an Infant with Severe Atopic Dermatitis and Sensitization/Allergy to Food.

Giovannini M, Bolis M, Barni S, Liccioli G, Sarti L, Morelli S J Clin Med. 2023; 12(12).

PMID: 37373584 PMC: 10298914. DOI: 10.3390/jcm12123889.


References
1.
Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y . Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2017; 73(1):29-36. DOI: 10.1111/all.13239. View

2.
Sediva A, Kayserova J, Vernerova E, Polouckova A, Capkova S, Spisek R . Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol. 2008; 121(6):1515-6. DOI: 10.1016/j.jaci.2008.03.007. View

3.
Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

4.
De D, Kanwar A, Handa S . Comparative efficacy of Hanifin and Rajka's criteria and the UK working party's diagnostic criteria in diagnosis of atopic dermatitis in a hospital setting in North India. J Eur Acad Dermatol Venereol. 2006; 20(7):853-9. DOI: 10.1111/j.1468-3083.2006.01664.x. View

5.
Thaci D, Reitamo S, Gonzalez Ensenat M, Moss C, Boccaletti V, Cainelli T . Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008; 159(6):1348-56. DOI: 10.1111/j.1365-2133.2008.08813.x. View